Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein 1, putative | solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 599 aa | 605 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2972 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2922 | 0.9824 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.1704 | 0.5549 | 0.5549 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2922 | 0.9824 | 0.9706 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0341 | 0.0765 | 0.0765 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2922 | 0.9824 | 0.9706 |
Toxoplasma gondii | 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein | 0.0388 | 0.0931 | 0.5 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase R153.1, putative | 0.0341 | 0.0765 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2972 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2922 | 0.9824 | 0.9706 |
Schistosoma mansoni | camp-specific 35-cyclic phosphodiesterase | 0.0388 | 0.0931 | 0.0931 |
Loa Loa (eye worm) | hypothetical protein | 0.2922 | 0.9824 | 0.9824 |
Loa Loa (eye worm) | cyclic AMP specific phosphodiesterase PDE4D5A | 0.0341 | 0.0765 | 0.0765 |
Onchocerca volvulus | 0.2972 | 1 | 0.5 | |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1754 | 0.5725 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1754 | 0.5725 | 1 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2972 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2972 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0388 | 0.0931 | 0.0931 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1754 | 0.5725 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2972 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2972 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0388 | 0.0931 | 0.0931 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0388 | 0.0931 | 0.0931 |
Loa Loa (eye worm) | hypothetical protein | 0.0388 | 0.0931 | 0.0931 |
Mycobacterium ulcerans | hypothetical protein | 0.1754 | 0.5725 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2972 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0341 | 0.0765 | 0.0765 |
Giardia lamblia | Hypothetical protein | 0.1754 | 0.5725 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0388 | 0.0931 | 0.0931 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 58.1 % | Inhibition of mouse GAT2 expressed in HEK cells assessed as remaining [3H]-GABA uptake at 100 uM after 25 mins by liquid scintillation counting analysis relative to control | ChEMBL. | 23598250 |
Activity (binding) | = 62 % | Inhibition of mouse GAT3 expressed in HEK cells assessed as remaining [3H]-GABA uptake at 100 uM after 25 mins by liquid scintillation counting analysis relative to control | ChEMBL. | 23598250 |
IC50 (binding) | = 5.05 | Inhibition of mouse GAT1 expressed in HEK cells assessed as inhibition of [3H]-GABA uptake after 25 mins by liquid scintillation counting analysis | ChEMBL. | 23598250 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.